MedTrace Logo

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

NCT03479372 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2019-07-09

No results posted yet for this study

Summary

Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

PAN-90806 Ophthalmic Suspension

PAN-90806 provided in single-use dropper bottles for topical ocular administration

Sponsors & Collaborators

  • PanOptica, Inc.

    lead INDUSTRY

Principal Investigators

  • Martin Wax, MD · PanOptica, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2019-05-27
Completion
2019-06-27
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Hungary
  • Latvia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03479372 on ClinicalTrials.gov